The monovalent nature of the molecule and lack of the mAb Fc are designed to minimize or eliminate the risk for platelet aggregation and thromboembolisms observed with the anti-CD40L mAbs in IgG1 format. This evidence concerns the gene CD40LG and Thromboembolism.